<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>日本制药公司大冢制药（Daiichi Sankyo Co. Ltd.，DSKYF,4568.T, DSNKY）周一报告称，截至 2026 年 3 月 31 日的财年净收入较上年下降。</p>
<p>2026 财年，归属于公司所有者的利润下降 12.1%，从前一年的 2957.6 亿日元降至 2598.7 亿日元。</p>
<p>每股收益为 140.37 日元，而去年为 155.87 日元。</p>
<p>核心营业利润从前一年的 3128.4 亿日元跃升至 359 亿日元。</p>
<p>营业利润从去年同期的 3319.3 亿日元下降 31%，降至 2290.9 亿日元。</p>
<p>收入从前一年的 1890 亿日元增加至 2120 亿日元。</p>
<p>展望未来，公司预计 2027 财年收入为 2280 亿日元，核心营业利润为 360 亿日元，而营业利润预计为 315 亿日元。</p>
<p>对于 2027 财年，公司预计归属于公司所有者的利润为 2600 亿日元，基本每股收益为 142.88 日元。</p>
<p>大冢制药在东京证券交易所收盘上涨 2.04%，报 2649 日元。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

4568

<p>第一三共株式会社报告截至 2026 年 3 月 31 日的财年净收入下降 12.1%，归属于股东的利润为 2598.7 亿日元。每股收益降至 140.37 日元。尽管收入增加至 2.12 万亿日元，营业利润却下降 31%，降至 2290.9 亿日元。对于 2027 财年，公司预计收入为 2.28 万亿日元，利润为 2600 亿日元，每股收益预计为 142.88 日元。该股在东京证券交易所上涨 2.04%，报 2649 日元</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Daiichi Sankyo Co. Ltd. (DSKYF,4568.T, DSNKY), a Japanese pharmaceutical company, on Monday reported lower net income in the full year ended March 31, 2026 compared with the previous year.</p>
<div class="lb-trans"><p>日本制药公司大冢制药（Daiichi Sankyo Co. Ltd.，DSKYF,4568.T, DSNKY）周一报告称，截至 2026 年 3 月 31 日的财年净收入较上年下降。</p>
</div><p>For the full year 2026, profit attributable to the owners of the company declined 12.1 percent to 259.87 billion from 295.76 billion in the prior year.</p>
<div class="lb-trans"><p>2026 财年，归属于公司所有者的利润下降 12.1%，从前一年的 2957.6 亿日元降至 2598.7 亿日元。</p>
</div><p>Earnings per share were 140.37 yen versus 155.87 last year.</p>
<div class="lb-trans"><p>每股收益为 140.37 日元，而去年为 155.87 日元。</p>
</div><p>Core operating profit jumped to 3.59 billion yen from 312.84 billion yen in the prior year.</p>
<div class="lb-trans"><p>核心营业利润从前一年的 3128.4 亿日元跃升至 359 亿日元。</p>
</div><p>Operating profit declined 31 percent to 229.09 billion yen from 331.93 billion in the same period last year.</p>
<div class="lb-trans"><p>营业利润从去年同期的 3319.3 亿日元下降 31%，降至 2290.9 亿日元。</p>
</div><p>Revenue increased to 2.12 trillion yen from 1.89 trillion yen in the previous year.</p>
<div class="lb-trans"><p>收入从前一年的 1890 亿日元增加至 2120 亿日元。</p>
</div><p>Looking ahead, the company expects revenue of 2.28 trillion yen and core operating profit of 360 billion yen, while operating profit is expected to be 315 billion yen for the full year ending March 31, 2027.</p>
<div class="lb-trans"><p>展望未来，公司预计 2027 财年收入为 2280 亿日元，核心营业利润为 360 亿日元，而营业利润预计为 315 亿日元。</p>
</div><p>For the full year 2027, the company expects profit attributable to the owners of the company to be 260 billion yen with basic earnings per share of 142.88.</p>
<div class="lb-trans"><p>对于 2027 财年，公司预计归属于公司所有者的利润为 2600 亿日元，基本每股收益为 142.88 日元。</p>
</div><p>Daiichi Sankyo closed trading 2.04% higher at JPY 2,649 on the Tokyo Stock Exchange.</p>
<div class="lb-trans"><p>大冢制药在东京证券交易所收盘上涨 2.04%，报 2649 日元。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

第一三共收益下降；发布 2027 财年指引